Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Inovio Pharmaceuticals Inc.
Headquarters: Plymouth Meeting, PA, United States of America
Website: http://www.inovio.com
Year Founded: 1983
Status: Public
Industry Sector: HealthTechnology
CEO: Jacqueline E. Shea, PhD
Number Of Employees: 134
Enterprise Value: $-32,543,963
PE Ratio: -0.4
Exchange/Ticker 1: NASDAQ:INO
Exchange/Ticker 2: N/A
Latest Market Cap: $58,300,800
BioCentury | Dec 14, 2024
Finance
Data spells money for a quintet of biotechs
NewAmsterdam’s CETP readout leads to week’s largest follow-on
BioCentury | Jul 3, 2024
Management Tracks
Dahan succeeds Saad as Alkeus CEO
Plus: Fox becomes interim CEO of Alphina and updates from Inovio and BenevolentAI
BioCentury | Apr 10, 2024
Product Development
AACR roundup: BioNTech shows personalized neoantigen vaccines are durable
Plus: Readouts from Geneos, BMS and Nurix
BioCentury | Apr 18, 2023
Deals
April 17 Quick Takes: J&J, Pipeline in deal for remyelination therapy for MS
Plus: FDA approves Gamida Cell’s omidubicel and updates from Vaxcyte, Otsuka, Lundbeck, Innoviva and more
BioCentury | Apr 7, 2023
Emerging Company Profile
Geneos: DNA-based, personalized cancer vaccines
Inovio spin-out combining parent company’s plasmid delivery system with neoantigen technology from David Weiner’s lab at Wistar
BioCentury | Sep 26, 2022
Emerging Company Profile
AstriVax: thermostable, plug-and-play vaccines using plasmids
V-Bio Ventures and Fund+ lead €30M seed round for KU Leuven spinout
BioCentury | Jul 20, 2022
Finance
July 19 Quick Takes: Frontera raises $160M series B
Plus Avista, Roche partner and updates from Novartis, Merck and more
BioCentury | May 11, 2022
Management Tracks
Shea replacing Kim as CEO of Inovio
Plus new chief commercial officer at DNA Script, and updates from Boston Pharma, Quantum SI, Beta, Longeveron and more
BioCentury | Mar 25, 2022
Regulation
March 24 Quick Takes: Lilly, Innovent weigh next steps after setback at FDA for PD-1 therapy
Plus: Imfinzi misses and updates from Chugai, YishengBio and more
BioCentury | Mar 3, 2022
Deals
March 2 Quick Takes: Sanofi adds mAb masking tech in Adagene deal
Plus NIH ends only active arm in ACTIV-2 and updates from Oculis, Ampio, Inovio, Epsilogen, Lexeo, BlueWillow-Medigen, Epigeneron
Items per page:
1 - 10 of 217